Compare MBBC & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | TCRX |
|---|---|---|
| Founded | 1902 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 49.4M |
| IPO Year | 2020 | 2021 |
| Metric | MBBC | TCRX |
|---|---|---|
| Price | $15.10 | $0.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 3.8K | ★ 761.4K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3200.00 | 12.28 |
| EPS | ★ 0.66 | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.88 | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $10.53 | $0.22 |
| 52 Week High | $15.79 | $2.57 |
| Indicator | MBBC | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 24.14 |
| Support Level | $14.58 | N/A |
| Resistance Level | $15.41 | $0.37 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 63.46 | 12.62 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.